APOC3 and hypertriglyceridemia: ApoC3 has therefore become an increasingly attractive target for reducing cardiovascular risk in patients with hypertriglyceridemia, with several antisense oligonucleotide therapies and hepatocyte‐targeted siRNAs being developed against ApoC3 [40, 41, 42, 43].